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Abstract
Background: The heat shock proteins (Hsps) are induced by stresses such as allergic factors and
inflammatory responses in bronchi epithelial cells and therefore may be detectable in patients with
asthma. However, the etiologic link between anti-Hsps and asthma (its severity and related
inflammatory responses such as interleukin-4 and immunoglobulin E) has not been established. We
determined whether antibodies against Hsp60 and Hsp70 were present in patients with asthma and
evaluated their associations with risk and severity of asthma.
Methods: We determined the levels of anti-Hsp60 and anti-Hsp70 by immunoblot and their
associations with risk and symptom severity of asthma in 95 patients with asthma and 99 matched
non-symptomatic controls using multivariate logistic regression analysis.
Results: Compared to the controls, asthma patients were more likely to have detectable anti-
Hsp60 (17.2% vs 5.1%) and anti-Hsp70 (33.7% vs 8.1%) (p ≤ 0.001). In particular, the presence of
anti-Hsp70 was associated with a greater than 2 fold risk for asthma (adjusted OR = 2.21; 95% CI
= 1.35~3.59). Furthermore, both anti-Hsp60 and anti-Hsp70 levels were positively correlated with
symptom severity (p < 0.05) as well as interleukin-4 and immunoglobulin E (p < 0.05). Individuals
with antibodies against anti-Hsp60 and anti-Hsp70 were more likely to have a family history of
asthma (p < 0.001) and higher plasma concentrations of total immunoglobulin E (p = 0.001) and
interleukin-4 (p < 0.05) than those without antibodies.
Conclusions: These data suggest that anti-Hsp60 and especially anti-Hsp70 correlate with the
attacks and severity of asthma. The underlying molecular mechanisms linking antibodies to heat
shock proteins and asthma remain to be investigated.
Background
Heat shock proteins (Hsps) are highly conserved proteins
inducible in response to a wide variety of stresses (such as
exposure to heat) and pathological (viral, bacterial or par-
asitic infections, and inflammation) or physiological
(growth factors, cell differentiation, and hormonal
Published: 14 February 2005
Respiratory Research 2005, 6:18 doi:10.1186/1465-9921-6-18
Received: 24 November 2004
Accepted: 14 February 2005
This article is available from: http://respiratory-research.com/content/6/1/18
© 2005 Yang et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Respiratory Research 2005, 6:18 http://respiratory-research.com/content/6/1/18
Page 2 of 8
(page number not for citation purposes)
stimulation) stimuli [1,2]. There are six main Hsp families
(i.e., Hsp110, Hsp90, Hsp/Hsc70, Hsp60, Hsp40, and
Hsp10-30) categorized on the basis of their apparent
molecular masses detected by sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE). Hsps are
involved in various biological functions including 1)
intracellular chaperones of naive, aberrantly folded or
mutated proteins, 2) cytokines of signal transduction cas-
cades involved in inflammatory response, and 3) cytopro-
tective agents in response to the aforementioned stress
stimuli [1,3,4]. In addition, Hsps are also involved in
transport of proteins and peptides through cellular com-
partments, and can bind to endogenous antigenic pep-
tides and transport them to the major histocompatibility
complexes [5,6]. This suggests that Hsps may modulate
immune and inflammatory responses and may be
involved in the pathogenesis and/or be markers for risk
and prognosis of certain diseases including asthma [7-13],
given that many of the stress stimuli mentioned above are
factors that can induce attacks of asthma.
Asthma is a multifactorial and likely multigenic immune
inflammatory disease of the upper airways, arising from
complex interactions among environmental and genetic
factors [14,15]. These factors may induce Hsp60 and
Hsp70 in bronchi epithelial cells during the development
of asthma [16]. Some Hsps present as self-antigens to the
immune system, resulting in the production of autoanti-
bodies in patients with inflammatory diseases and
immune disorders after infections by bacteria, mycobacte-
ria and Chlamydia [17-19]. Studies have demonstrated
that these autoantibodies against Hsps were involved in
the pathogenesis and/or prognosis of some diseases [8,20-
23].
Up to now, few studies investigated possible associations
of autoantibodies to human Hsps with the severity of
asthma. In the present study, we determined the presence
of autoantibodies to human Hsp60 and Hsp70 in 193
subjects with (n = 95) and without (n = 99) asthma by
immunoblot analysis, and evaluated the associations of
these autoantibodies with asthma severity and their corre-
lation with interleukin-4 (IL-4) and immunoglobulin E
(IgE) both involved in the development of asthma, by
using multivariate logistic regression analyses.
Methods
Subjects and groups
This 95 patients with asthma (54 males and 41 females)
and 99 healthy, age-matched non-asthmatic controls (64
males and 35 females) were residents living in the same
geographic area. Patients and controls were from
Wuchang, one of the three cities of Wuhan and were all of
Han nationality. Their age ranged from 10 to 45 years old
(Table 1). All 95 patients were diagnosed according to
diagnostic criteria and principles of management of
asthma proposed by the American Thoracic Society [24]
and did not have other pulmonary, cardiovascular and
gastro-duodenal diseases. A standardized questionnaire
was completed for each individual by physicians with
extensive experience in allergic and immune diseases to
obtain demographic information and known risk factors
for asthma including personal and family history of
asthma and frequency of attacks. Selection criteria for the
controls included the absence of any personal history of
asthma. Health examination and physical sign findings
such as wheezing and forced expiratory volume
(FEV%Pre) were also recorded. Neither patients nor con-
trols had any history of chronic diseases such as cancer,
diabetes, cardiovascular diseases and gastro-duodenal dis-
eases. Patients with asthma were grouped by symptom
severity and medication use according to the 2002 Global
Initiative for Asthma Guidance [25] as intermittent, mild
persistent, moderate persistent and severe persistent.
Venous blood was collected into heparinized tubes to sep-
arate plasma for the detection of anti-Hsp60 and anti-
Hsp70 as well as IgE and IL-4. Plasma samples from
patients and controls were stored in aliquots at -80°C and
thawed only once immediately before the tests were per-
formed. Written informed consent was obtained from
patients and controls, and the study was approved by the
Tongji Medical College Ethics Committee.
Table 1: Comparison of selected variables between patients with asthma and healthy controls
Patients with asthma (n = 95) Control subjects (n = 99) P value
Sex (M/F) 54/41 64/35 0.266
Age (years, mean ± SD) 28.2 ± 15.8 29.1 ± 13.9 0.680
Attack once a week or a day (yes/no) 95/95 0/99 <0.000
Sign (wheezing) (yes/no) 95/95 0/99 <0.000
FEV1%Pre 58.4 ± 18.9 96.5 ± 9.8 <0.001
IgE (IU/ml, mean ± SD) 486.9 ± 595.5 75.8 ± 124.9 <0.001
IL-4 (ng/L, mean ± SD) 31.7 ± 17.1 5.1 ± 3.8 <0.001Respiratory Research 2005, 6:18 http://respiratory-research.com/content/6/1/18
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Determination of anti-Hsp60 and anti-Hsp70
Recombinant human Hsp60 and inducible Hsp70 were
obtained through the expression of corresponding cDNA
in NaCl-induced E. coli GJ1168 cells using pET30 (Nove-
gen) as the expression vector [26]. Approximately 10–15
µg of recombinant human Hsp60 or Hsp70 was loaded
on each SDS-PAGE gel without combs, separated, and
transferred by electrophoresis to nitrocellulose mem-
branes. The band containing Hsp60 or Hsp70 was cut into
2 mm × 3 mm pieces and marked with a small red dot on
the protein side of the membrane. These membrane
pieces were placed in individual wells of an ELISA plate,
rinsed with PBS, saturated with 100 µl of blocking buffer
(PBS containing 5% skim milk powder) for 1 h at 37°C
with gentle agitation and washed with PBS-0.05% Tween
80 for 5 min. The plasma diluted 1:10, 1:20, 1:40 and
1:80 in 100 µl PBS containing 5% skim milk powder was
incubated with the membrane pieces at 37°C for 2 h with
gentle agitation. After washing the membrane pieces six
times (10 min each) with 200 µl PBS-0.05% Tween 80,
100 µl of HRP labelled goat anti-human IgG (Sigma) in
blocking buffer (1:2500) was added and the incubation
continued at 37°C for 1 h. The membrane pieces were
washed again six times (10 min) with 200 µl PBS-0.05%
Tween 80. The presence of anti-Hsp60 or anti-Hsp70 was
then revealed with DAB (3,3-diaminobenzidine tetra
hydrochloride) for 3–5 min. A visible brown band on the
membrane piece was regarded as a positive test and a col-
ourless membrane as a negative test [21,22]. An example
of the microblot technique is shown in Figure 1. Samples
were scored in a double blind manner by three different
investigators.
Detection of plasma IgE and IL-4
Total IgE was measured in plasma by using a fluorescence
enzyme immunoassay kit from Bayer Company
(Leverkusen, Germany). IL-4 was determined using a
commercial enzyme-linked immunosorbent assay kit
from OptEIA (Pharmingen, California, U.S.A). Each sam-
ple was tested in duplicate by a series of dilutions using a
standard provided with the kit.
Statistical analyses
All the continuous data (e.g., age, FEV1, IGE, IL4) were
presented as the mean ± standard deviation (SD) and ana-
lysed by the Student's t test. Frequency data (e.g., sex) were
analysed by the Chi-square test. The associations were
estimated by fitting univariate and multivariate logistic
regression models. Statistical inferences were based on a
significance level of 0.05. All analyses were two-sided and
performed by using the Statistical Package for Social Sci-
ences (SPSS) software (Version, Chicago).
Results
The patient and control groups comprised 56.8% and
64.6% of males, respectively, and had mean ages of 28.2
and 29.1 years, respectively (Table 1). All patients had reg-
ular asthma attacks and sign of wheezing, while none of
the controls showed any of these signs. Asthma patients
had a significantly lower FEV1%Pre than the controls
(58.4 vs 96.5, p < 0.001). In addition, the asthma patients
had significantly higher concentrations of total IgE and IL-
4 than the controls (p < 0.001 for all comparisons).
Presence of anti-Hsp60 and anti-Hsp70 in plasma
We first looked for the presence of anti-Hsp60 and anti-
Hsp70 in plasma at dilutions of 1:10 to 1:80 in the
patients with asthma and in the matched controls. At a
dilution of 1:10, asthma patients had a significantly
higher positive rate of anti-Hsp60 than the controls
(17.9% vs 5.1%, p = 0.001). In the case of Hsp70, anti-
bodies were observed in 33.7% of patients as compared to
8.1% in the controls at a dilution of 1:10 (p < 0.001). At
plasma dilutions between 1:20 to 1:80, the difference in
the detection rates of both anti-Hsp60 and anti-Hsp70
between the patients and controls remained highly signif-
icant (Table 2). The combined detection rate of both anti-
Hsp60 and anti-Hsp70) at the lower plasma dilution
(1:10) was also globally much higher in the asthma
patients (38.9%) than in the controls (9.1%).
Association between anti-Hsp60 and anti-Hsp70 with risk 
for asthma
Further analysis for asthma risk factors (sex, age, family
history) and anti-Hsp60 and anti-Hsp70 was carried out
Purified recombinant Hsp70 was electrophoresed in SDS- PAGE, transferred to nitrocellulose membranes and cut into  2 – 3 mm wide strips Figure 1
Purified recombinant Hsp70 was electrophoresed in SDS-
PAGE, transferred to nitrocellulose membranes and cut into 
2 – 3 mm wide strips. These were incubated with the plasma 
and the presence of antibodies to Hsp70 detected as 
described in Methods. Lane 1 – 3: positive; Lane 4: negative.Respiratory Research 2005, 6:18 http://respiratory-research.com/content/6/1/18
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by using a multivariate logistic regression model built
with a forward stepwise selection procedure (p values for
entry and removal, 0.10) and also based on clinical
experience. The results in Table 3 show a statistically sig-
nificant positive association between the presence of anti-
Hsp70 and risk for asthma (p = 0.001), representing a
greater than 2-fold increased risk for asthma (adjusted OR
= 2.21; 95% CI = 1.35~3.59) (Table 3). However, no sig-
nificant association of anti-Hsp60 with risk for asthma
was found (p = 0.161).
Correlation of anti-Hsp60 and anti-Hsp70 with the 
severity of asthma
To understand the possible significance of the anti-Hsp60
and anti-Hsp70 in asthma, we analyzed the correlation of
anti-Hsp60 and anti-Hsp70 with the severity of asthma.
Table 4 shows that there was a significant increase of pos-
itive rates and dilutions of anti-Hsp60 and anti-Hsp70 as
the severity of asthma increased. This table also shows
that there were significantly positive correlations of anti-
Hsp60 and anti-Hsp70 with the numerical categories of
symptom severity (p < 0.05)
Differences in the levels of IgE and IL-4 between asthma 
patients with positive and negative anti-Hsps
We finally compared the levels of IgE and IL-4, two impor-
tant known risk factors for asthma, in the 95 asthma
patients who were either positive (37 patients) or negative
(58 patients) for the presence of anti-Hsp60 and anti-
Hsp70. The patients positive for anti-Hsps were more
likely than the antibody-negative group of patients to
report a family history of asthma (48.6% Vs 13.8%, p <
0.001) and had higher concentrations of total IgE (758.2
Vs 313.9, P = 0.001) and IL-4 (36.9 Vs 28.5, p = 0.019)
(Table 5). Further analysis showed that the presence of
either anti-Hsp60 or anti-Hsp70 or both was significantly
correlated with the levels of IgE and IL-4 in asthma
patients (Table 6) (p < 0.05). These preliminary data also
Table 2: Comparison of positive rates of different titers for ant-Hsp60 and anti-Hsp70 in plasma of patients with asthma and healthy 
controls
Titers Patients with asthma (n = 95) Control subjects (n = 99) P value
n (%) n (%)
Anti-Hsp60 1:10 17 (17.9) 5 (5.1) 0.001
1:20 8 (8.4) 1 (1.0) 0.014
1:40 5 (5.3) 0 (0.0) 0.027
1:80 5 (5.3) 0 (0.0) 0.027
Anti-Hsp70 1:10 32 (33.7) 8 (8.1) <0.001
1:20 19 (20.0) 4 (4.0) <0.001
1:40 13 (13.7) 1 (1.0) <0.001
1:80 9 (9.5) 0 (0.0) 0.001
Anti-Hsps* 1:10 37 (38.9) 9 (9.1) <0.001
* Combined positive rate of anti-Hsp60 and /or anti-Hsp70 for titers 1:10–1:80.
Table 3: Multivariate logistic regression analysis of the association between anti-Hsp60 and anti-Hsp70 with risk for asthma
Variables* Adjusted Regression coefficient Standard error χ2 Value P value OR (95% CI)**
Constant -0.977 0.509 3.676 0.055
Sex 0.392 0.318 1.519 0.218 1.48 (0.79~2.76)
Age 0.017 0.109 0.026 0.872 1.02 (0.82~1.26)
Family history 0.602 0.219 8.215 0.085 2.01 (1.25~3.25)
Anti-Hsp60 0.459 0.328 1.965 0.161 1.58 (0.83~3.01)
Anti-Hsp70 0.794 0.248 10.224 0.001 2.21 (1.35~3.59)
*The dependent variable is the status of asthmas patient or control; the independent variables included Sex: 0 = male and 1 = female; Age: 
continuous variable in years; Family history: 0 = no and 1 = yes; Anti-Hsp60: 0 = negative and 1 = positive; Anti-Hsp70: 0 = negative and 1 = 
positive.
**OR, odds ratio, and CI, confidence interval.Respiratory Research 2005, 6:18 http://respiratory-research.com/content/6/1/18
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indicated a positive correlation between the presence of
these autoantibodies and the severity of the disease (r =
0.461, p < 0.001 for anti-hsp60 and r = 0.538, p < 0.001
for anti-Hsp70) (Table 6) as well as a statistically signifi-
cant correlation between anti-Hsp70 and anti-Hsp60 (r =
0.485, p < 0.001) by using the rank correlation analysis.
Discussion
The patients included in the present study had frequent
asthmatic attacks, with signs of wheezing and higher lev-
els of IgE and IL4 and low levels of FEV1 %Pre that are
characteristics of asthma. We found that these asthma
patients also had a significantly higher incidence of
autoantibodies against combined Hsp60 and Hsp70 than
the matched non-asthmatic controls and that, in
particular, the presence of anti-Hsp70 was associated with
asthma. Furthermore, there was a significant positive
correlation between anti-Hsp60 and anti-Hsp70 and
symptom severity of asthma. Thus among asthma
patients, those who had positive anti-Hsp60 and anti-
Hsp70 were more likely to report a family history of
asthma and had higher levels of IgE and IL-4 than those
without such antibodies. These findings provide evidence
to support the hypothesis that the presence of anti-Hsp60
and especially anti-Hsp70 in asthma patients is strongly
associated with asthma and the presence of these antibod-
ies may predict symptom severity of asthma and provide
new strategies for diagnosis and perhaps treatment of this
disease.
Table 4: Correlation of anti-Hsp70 and anti-Hsp60 with symptom severities
Symptom Severity No. Anti-Hsp70 No. (%) Anti-Hsp60 No. (%)
1:10 1:20 1:40 1:80 1:10 1:20 1:40 1:80
Step1: intermittent 30 2 (6.7) 0 (0.0) 0 (0.0)0  ( 0 . 0 )0  ( 0 . 0 )0  ( 0 . 0 )0  ( 0 . 0 )0  ( 0 . 0 )
Step2: mild persistent 36 10 (27.8) 5 (13.9) 2 (5. 6 )1  ( 2 . 8 )3  ( 8 . 3 )1  (2.8) 1 (2.8) 1 (2.8)
Step3&4 moderate & severe persistent** 29 20 (69.0) 14 (48.3) 11 (37.9) 8 27.6) 14 (48.3) 5 (17.2) 4 (14.0) 4 (14.0)
R value* 0.809 0.958 0.968 0.959 0.954 0.864 0.947 0.947
P value* 0.000 0.000 0.000 0.001 0.000 0.000 0.016 0.016
* The analyses of correlation of symptom severities with different dilutions of anti-Hsp70 and anti-Hsp60
**: there are two severe persistent patients with asthma
Table 5: Differences in selected risk factors, IgE, and IL-4 between asthma patients with positive and negative anti-Hsps
Anti-Hsps(+) (n = 37) Anti-Hsps(-) (n = 58) P value
Sex (M/F) 23/14 31/27 0.403
Age (years, mean ± SD) 25.6 ± 15.6 29.3 ± 15.7 0.249
Family history (yes/no) 18/19 8/50 <0.001
IgE (IU/ml, mean ± SD) 758.2 ± 685.3 313.9 ± 458.2 0.001
IL-4 (ng/L, mean ± SD) 36.9 ± 17.2 28.5 ± 16.3 0.019
Table 6: Correlation between anti-Hsps, IgE, and IL-4 in 95 asthma patients
IgE IL-4 Anti-Hsp70 Anti-Hsp60 Anti-Hsps
rPrPrPrPrP
IL-4 0.701 <0.001
Anti-Hsp70 0.369 <0.001 0.222 0.010
Anti-Hsp60 0.262 0.010 0.259 0.011 0.485 <0.001
Anti-Hsps 0.366 <0.001 0.241 0.019 0.534 <0.001 0.814 <0.001
Asthma severity 0.330 0.001 0.236 0.022 0.461 <0.001 0.538 <0.001 0.417 <0.001Respiratory Research 2005, 6:18 http://respiratory-research.com/content/6/1/18
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Asthma is an immune and inflammatory disease, arising
from complex interactions among genetic and environ-
mental factors including bacterial or viral infection
[14,15]. The production of autoantibodies against Hsps
may result from genetic factors, infection, denaturation
and release of Hsps as a result of cell damage, and the
presence of antigen-specific lymphocytes [22,23].
Hsps are often the target of humoral and T cell-mediated
immune responses to infection and may provide a link
between the immune response to infection and autoim-
munity caused by T lymphocyte cross-reactivity among
Hsps of different origins [8,27,28]. It remains to be deter-
mined whether there is a relationship between the induc-
tion of Hsp70 and production of plasma autoantibodies
against this Hsp and whether there is a cross-response of
induced Hsps and autoantibodies against Hsps before and
during the development of asthma. However, there are
several lines of evidence that support an association
between anti-Hsp60 and anti-Hsp70 and symptom sever-
ity in asthma patients. Firstly, as molecular chaperones,
Hsps facilitate the synthesis, folding, assembly and intrac-
ellular trafficking of many functional proteins [3,29] and
protect cells and organs against different types of damages
[30,31] as observed in transient protection from ischemic
injury in whole organs such as heart, brain and kidney
[31-34]. Hsp70 has also been suggested to play an auto-
protective role in asthma and lung injury [35-37]. Sec-
ondly, autoantibodies against Hsps may have significant
roles in the pathogenesis and prognosis of diseases. For
example, Shinghai et al reported the presence of antibod-
ies against Hsps in patients with autoimmune liver dis-
eases and suggested that the presence of anti-Hsp70 was
an indicator for the disease activity of primary biliary cir-
rhosis [8]. Earlier results from our lab also suggested that
the presence of such antibodies might help assess if work-
ers are experiencing abnormal stress within their living
and working environment [21-23]. Xu et al and Schett et
al have shown that mycobacterial Hsp65 may serve as an
antigen to instigate chronic immune responses character-
istic of human atherosclerosis. These antibodies were sus-
tained among patients with the most severe degree of
underlying atherosclerosis and were demonstrated to pre-
dict 5-year mortality [11,12,20]. Thirdly, enhanced
expression of Hsp70 has been detected in bronchi and
alveolar macrophages of patients with asthma and corre-
lated with intrapulmonary eosinophilia, airway inflam-
mation, hyperresponsiveness of bronchi [38], and severity
of the disease [14,35,39]. A cross-response of induced
plasma and cellular Hsps and autoantibodies against
Hsps in human, has been suggested to play a role in the
development and prognosis of atherosclerosis [40,41].
However, it is still unknown whether there is a cross-
response between the induction of Hsps in bronchi of
patients with asthma and the presence of anti-Hsps and its
biological effects.
The development of most immune diseases depends on
the cytokines interleukin-2 and interferon-γ produced by
type 1 helper T cells (Th1), whereas the development of
allergic diseases requires IL-4 and IL-5, both of which are
produced by type 2 helper T cells (Th2). The reciprocal
down-regulation of Th1 cells by Th2 cytokines raises the
possibility that these cytokines are involved in allergy or
immunity [42]. IL-4 is one of the first signals for a switch
to the synthesis of IgE and IL-4 binds to receptors on B
cells to induce and amplify the synthesis of IgE [43]. There
is a cross-linking of IgE with allergens to activate a series
of response seen in asthma [44]. Epidemiological and
clinical observations have linked IgE antibodies to the
severity of asthma and the initial and sustained responses
of the airways to allergens [45,46]. At this time, the molec-
ular events that link antibody to Hsp70 to the production
of IL-4 and IgE and the interaction among these factors in
patients with asthma remain to be investigated.
Conclusions
The present study showed that there was a significant
increase in positive rates of antibodies against Hsp60 and
Hsp70 in patients with asthma and that the presence of
autoantibodies against Hsp70 was associated with the
severity of asthma. The presence of anti-Hsp70 associated
with a high risk of asthma was also correlated with the
family history of asthma and higher levels of total IgE and
IL-4 in the patients. These results suggest that anti-Hsp70
correlate with the pathogenesis of asthma, but the precise
underlying molecular mechanisms for these interactions
remain to be established.
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